Resources 
Product Resource
Learning
We Are Pleased to Announce: Global Commercial Licensing Rights for Jurkat E6.1, CHO-K1, and HEK293 Cell Lines Officially Secured.
ExploreArticles
IL-33: A Multifaceted Inflammatory Alarmin and Cell Models for Drug Screening
The IL-33/ST2 axis links tissue damage to immune responses, and its translational potential has become clearer as programs such as tozorakimab and astegolimab have advanced clinically. Across COPD, atopic dermatitis, asthma, and combination cancer immunotherapy, the pathway has broad therapeutic potential. Reqbio’s adherent and suspension IL-33 effector reporter cell models combine sensitive functional readouts with flexible assay formats for drug discovery and development. Using functional cell engineering and precision gene-editing platforms, Reqbio provides drug-testing cell models spanning GPCR, immuno-oncology, kinase, and other target classes, together with cell-based bioactivity assay services.
TRKA Target: A Dual Engine Bridging Neural Regulation and Pan-Cancer Therapy
TRKA is a key therapeutic target with dual roles in neural development and pan-cancer progression. As both the core receptor in the NGF pain signaling pathway and a major oncogenic driver in NTRK fusion-positive tumors, TRKA has become a focal point in modern drug discovery.
TRKA Cell Models – Empowering Dual-Target Drug Discovery in Neuroscience and Oncology
Stable TRKA reporter gene cells and CHO-K1 cell lines for agonist/inhibitor screening and pathway analysis.Reqbio provides NGF/hTRKA and NGF/Canine TRKA reporter gene cells as well as TRKA CHO-K1 stable cell lines for TRKA agonist/inhibitor screening and mechanism studies.
LTBR Cell Models – Reporter Cell Lines & CHO-K1 Cell Lines | Reqbio
LTBR activation induces TLS formation by recruiting T and B cells via chemokines (CXCL13, CCL19), thereby enhancing anti-tumor immunity. However, aberrant LTBR activation can also drive immunosuppressive macrophage polarization and promote tumor progression, giving LTBR a dual functional role in immuno-oncology. Reqbio offers an LTBR Effector Reporter Cell Line and an LTBR CHO-K1 Stable Cell Line for LTBR agonist screening and mechanistic studies. Both models have been validated by dose–response assays and ar
LTBR: From Tertiary Lymphoid Structure Formation to Cell-Based Models for Solid Tumor Immunotherapy
As a pivotal molecule at the intersection of lymphoid organ development, tertiary lymphoid structure formation, and tumor immunotherapy, LTBR is advancing from basic research toward clinical translation. With bispecific antibodies from Roche and Mestag now in clinical trials, LTBR agonist therapy is poised to become an important strategy in next-generation solid tumor immunotherapy. Reqbio’s LTBR effector reporter cell and LTBR CHO cell model — characterized by precise pathway design and rigorous functional validation — provide global drug developers with efficient, reliable evaluation tools to accelerate the advancement of LTBR-targeted therapeutics.
NPFFR2: Dual Neural-Metabolic Target for Pain, Anxiety & Obesity — Drug Discovery & Cell Models
NPFFR2 is a powerful neuro-metabolic dual switch and a high-potential target for treating pain, anxiety, opioid addiction, and obesity. The 2025 Cell Reports structural breakthrough has opened a new era of structure-based rational drug design.To achieve efficient and reliable drug R&D, researchers require rigorously validated stable NPFFR2 cell models to support agonist screening, cAMP inhibition, EC50 quantification, and mechanistic studies. These tools bridge structural biology and drug development, accelerating hit compound discovery, strengthening candidate optimization, and promoting clinical translation.
